03.18.25 -- BoB@JPM: Ran Zheng, Landmark Bio

Explore how the ADC landscape is being reshaped by new drug product capabilities that enable end-to-end development and manufacturing of cytotoxic bioconjugates.

Discover how Boehringer Ingelheim’s expertise in plasmid DNA manufacturing can propel your innovative therapies forward and transform patient care.

The revised EU GMP Annex 1 mandates a comprehensive Contamination Control Strategy and continuous environmental monitoring to ensure sterile manufacturing compliance.

Technical transfers are one of the most critical, yet challenging steps in drug development; therefore, an effective strategy is essential to accelerate the translation of projects from bench to market.

Review the importance of alternative approaches to viral vector production and the benefits of intensified adherent cell culture for improving efficiency, reducing costs, and accelerating development.

Discover how implementing a strategic approach to optimize the platform can establish a solid foundation for the efficient, reliable, and successful manufacturing of biopharmaceutical products.

Cory Lewis, CEO of INCOG Biopharma Services, explains how the company is adapting with rapid growth to deliver customizable and flexible solutions from early development support to commercial filling.

COVID-19 reshaped the pharmaceutical landscape, and its impact on the supply chain is undeniable. As the industry adapts to a new reality, executives are prioritizing reliable, forward-thinking partnerships.

Discover insights tailored specifically for drug product researchers and manufacturers, offering key knowledge on extractables, leachables, and effective implementation strategies.

With extensive experience in managing assay transfers across diverse sources and development stages, we have identified five factors that can impact the success of potency assay transfers.